A Phase 3 interventional study of nivolumab and paclitaxel (PTX) in Breast Cancer, sponsored by Bristol-Myers Squibb. Completed at 240 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.
Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 10 that started in 2019, is the only one in phase 3, and was the 22nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Women only
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 1
First in 2015; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 521 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 47 across the 22 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2019, is one of 2 in phase 3, and was the 39th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
1 of the studies testing nivolumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03546686University of Texas Southwestern Medical CenterPeri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing nivolumab in Breast Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
Biological: nivolumab · Drug: paclitaxel (PTX) · Drug: anthracycline · Drug: cyclophosphamide · Drug: Endocrine Therapy · Procedure: Surgery
Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then adjuvant (post-surgery) endocrine therapy of investigator's choice
Drug: paclitaxel (PTX) · Other: nivolumab placebo · Drug: anthracycline · Drug: cyclophosphamide · Drug: Endocrine Therapy · Procedure: Surgery
Specified Dose on Specified days
Specified dose on Specified days
Specified dose on Specified days
Specified dose on Specified days
Specified dose on Specified days
Variable endocrine therapy of investigators choice
Surgery for breast cancer
Pathological Complete Response (pCR) Rate
pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.
Time frame: Up to approximately 37 months
Pathological Complete Response (pCR) Rate (PD-L1 >=1%)
pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.
Time frame: Up to approximately 37 months
Number of Participants With Residual Cancer Burden (RCB)
RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.
Time frame: Up to approximately 37 months
Number of Participants With Residual Cancer Burden (RCB) PD-L1 >=1%
RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.
Time frame: Up to approximately 37 months
Number of Participants With Adverse Events (AEs)
Number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants with any grade serious adverse events (SAE). SAE is defined as any untoward medical occurrence that, at any dose: Results in death; is life threatening; requires inpatient hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)
Number of Participants Who Died
Number of participants who died due to any cause.
Time frame: Up to approximately 41 months
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 263 | 258 |
| Completed | 260 | 257 |
| Not completed | 3 | 1 |
| Withdrew: Participant withdrew consent | 2 | 0 |
| Withdrew: Participant no longer meets study criteria | 1 | 1 |
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 260 | 257 |
| Received arm a treatment | 0 | 2 |
| Completed | 167 | 174 |
| Not completed | 93 | 83 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Adverse event | 23 | 7 |
| Withdrew: Participant request to discontinue study treatment | 15 | 14 |
| Withdrew: Withdrawal by subject | 8 | 8 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Participant no longer meets study criteria | 2 | 2 |
| Withdrew: Administrative reasons by sponsor | 2 | 3 |
| Withdrew: Other reasons | 17 | 23 |
| Withdrew: Disease progression | 4 | 7 |
| Withdrew: Study drug toxicity | 12 | 5 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 |
| Withdrew: Disease recurrence | 0 | 2 |
| Withdrew: Not reported | 4 | 8 |
pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Pathological Complete Response (pCR) Rate | 24.5 (19.4 to 30.2) | 13.8 (9.8 to 18.7) |
pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.
| Percentage of participants | Arm A | Arm B |
|---|---|---|
| Pathological Complete Response (pCR) Rate (PD-L1 >=1%) | 44.3 (33.7 to 55.3) | 20.2 (12.3 to 30.4) |
RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.
| Participants | Arm A | Arm B |
|---|---|---|
| RCB-0 | 62 | 34 |
| RCB-I | 17 | 20 |
| RCB-II | 90 | 106 |
| RCB-III | 57 | 73 |
| Not Reported | 31 | 20 |
RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.
| Participants | Arm A | Arm B |
|---|---|---|
| RCB-0 | 38 | 16 |
| RCB-I | 10 | 6 |
| RCB-II | 25 | 36 |
| RCB-III | 9 | 20 |
| Not Reported | 6 | 6 |
Number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| Participants | Arm A | Arm B |
|---|---|---|
| Adverse Events (AEs) | 259 | 252 |
| Drug-Related AEs | 254 | 236 |
| AEs leading to discontinuation | 41 | 14 |
Number of participants with any grade serious adverse events (SAE). SAE is defined as any untoward medical occurrence that, at any dose: Results in death; is life threatening; requires inpatient hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 80 | 45 |
Number of participants who died due to any cause.
| Participants | Arm A | Arm B |
|---|---|---|
| Number of Participants Who Died | 15 | 8 |
Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 41 months). SAEs and Other AEs were assessed from first dose up to 100 days post last dose (Up to approximately 21 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ET | 8/129 (6.2%) | 38/127 (29.9%) | 126/127 (99.2%) |
| Arm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ET | 7/136 (5.1%) | 51/135 (37.8%) | 132/135 (97.8%) |
| Arm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ET | 4/124 (3.2%) | 20/123 (16.3%) | 120/123 (97.6%) |
| Arm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET | 4/132 (3%) | 26/132 (19.7%) | 130/132 (98.5%) |
| Event | Arm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ET | Arm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ET | Arm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ET | Arm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/127 | 9/135 | 0/123 | 4/132 |
| COVID-19Infections and infestations | 2/127 | 5/135 | 2/123 | 1/132 |
| PyrexiaGeneral disorders | 0/127 | 4/135 | 0/123 | 0/132 |
| COVID-19 pneumoniaInfections and infestations | 3/127 | 1/135 | 0/123 | 0/132 |
| PneumoniaInfections and infestations | 1/127 | 3/135 | 1/123 | 3/132 |
| NeutropeniaBlood and lymphatic system disorders | 2/127 | 2/135 | 2/123 | 0/132 |
| DiarrhoeaGastrointestinal disorders | 0/127 | 0/135 | 2/123 | 0/132 |
| AnaemiaBlood and lymphatic system disorders | 2/127 | 2/135 | 0/123 | 0/132 |
| Postoperative wound infectionInfections and infestations | 2/127 | 1/135 | 0/123 | 0/132 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/127 | 0/135 | 0/123 | 1/132 |
| Event | Arm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ET | Arm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ET | Arm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ET | Arm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET |
|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 83/127 | 64/135 | 80/123 | 69/132 |
| NauseaGastrointestinal disorders | 61/127 | 77/135 | 55/123 | 59/132 |
| FatigueGeneral disorders | 34/127 | 67/135 | 24/123 | 52/132 |
| AnaemiaBlood and lymphatic system disorders | 47/127 | 65/135 | 32/123 | 62/132 |
| DiarrhoeaGastrointestinal disorders | 30/127 | 48/135 | 26/123 | 40/132 |
| HeadacheNervous system disorders | 24/127 | 43/135 | 24/123 | 33/132 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/127 | 41/135 | 20/123 | 42/132 |
| Neuropathy peripheralNervous system disorders | 26/127 | 38/135 | 19/123 | 32/132 |
| ConstipationGastrointestinal disorders | 23/127 | 36/135 | 19/123 | 30/132 |
| Aspartate aminotransferase increasedInvestigations | 32/127 | 30/135 | 23/123 | 19/132 |
| Age, Continuous(Years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 49.9 ± 12.0 | 50.9 ± 11.8 | 50.4 ± 11.9 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 262 | 257 | 519 |
| Male | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Hispanic or Latino | 74 | 80 | 154 |
| Not Hispanic or Latino | 102 | 121 | 223 |
| Unknown or Not Reported | 87 | 57 | 144 |
| Race (NIH/OMB)(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 18 | 17 | 35 |
| Asian | 24 | 18 | 42 |
| Native Hawaiian or Other Pacific Islander | 2 | 3 | 5 |
| Black or African American | 6 | 8 | 14 |
| White | 202 | 193 | 395 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 19 | 30 |
Showing the first 100 of 240 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2019 to primary completion in Jan 2023, 37 months.
Results were first posted in Mar 2024, 1 year 1 month after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 37 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab